PUBLISHER: QYResearch | PRODUCT CODE: 1313265
PUBLISHER: QYResearch | PRODUCT CODE: 1313265
Due to the COVID-19 pandemic, the global Recombinant Human Serum Albumin market size was US$ 74.84 million in 2022 and is forecast to a readjusted size of US$ 121.07 million by 2029 with a CAGR of 7.16% during the forecast period 2023-2029.
The North America Recombinant Human Serum Albumin market size was US$ 43.08 million in 2022, while China was US$ 2.16 million. The proportion of the North America was 57.56% in 2022, while Chinese percentage was 2.89%, and it is predicted that China share will reach 3.5% in 2029, trailing a CAGR of 9.87 % through the analysis period.
The global key manufacturers of Recombinant Human Serum Albumin include: Albumedix, Merck, Ventria (InVitria), NCPC, Oryzogen, HiMedia, and etc. In 2022, the global top five players occupied for a share approximately 90.81% in terms of revenue.
The global Recombinant Human Serum Albumin market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Recombinant Human Serum Albumin market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2018-2029.